Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Browse by Research Team

Group by: Date | Item Type | Source

Article

Anti-angiogenesis and anti-immunosuppression gene therapy through targeting COUP-TFII in an in situ glioblastoma mouse model.
Wang, F., Zhang, S., Sun, F., Chen, W., Liu, C., Dong, H., Cui, B., Li, L., Sun, C., Du, W., Liu, B., Fan, W., Deng, J., Schmitt, C.A., Wang, X. and Du, J.
Cancer Gene Therapy 31 (8): 1135-1150. August 2024

LncRNA MIR31HG fosters stemness malignant features of non-small cell lung cancer via H3K4me1- and H3K27Ace-mediated GLI2 expression.
Chen, W., Wang, F., Yu, X., Qi, J., Dong, H., Cui, B., Zhang, Q., Wu, Y., An, J., Ni, N., Liu, C., Han, Y., Zhang, S., Schmitt, C.A., Deng, J., Yu, Y. and Du, J.
Oncogene 43 (18): 1328-1340. 2 May 2024

Passenger gene coamplifications create collateral therapeutic vulnerabilities in cancer.
Bei, Y., Brame, Luca, Kirchner, M., Fritsche-Guenther, R., Kunz, S., Bhattacharya, A., Rusu, M.C., Gürgen, D., Dubois, F.P.B., Köppke, J.K.C., Proba, J., Wittstruck, N., Sidorova, O.A., Chamorro González, R., Dorado Garcia, H., Brückner, L., Xu, R., Giurgiu, M., Rodriguez-Fos, E., Yu, Q., Spanjaard, B., Koche, R.P., Schmitt, C.A., Schulte, J.H., Eggert, A., Haase, K., Kirwan, J., Hagemann, A.I., Mertins, P., Dörr, J.R. and Henssen, A.G.
Cancer Discovery 14 (3): 492-507. 1 March 2024

Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine - a prospective cohort study by the AGMT.
Pleyer, L., Vaisband, M., Drost, M., Pfeilstöcker, M., Stauder, R., Heibl, S., Sill, H., Girschikofsky, M., Stampfl-Mattersberger, M., Pichler, A., Hartmann, B., Petzer, A., Schreder, M., Schmitt, C.A., Vallet, S., Melchardt, T., Zebisch, A., Pichler, P., Zaborsky, N., Machherndl-Spandl, S., Wolf, D., Keil, F., Hasenauer, J., Larcher-Senn, J. and Greil, R.
American Journal of Hematology 98 (11): 1685-1698. November 2023

Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors.
Bonifacius, A., Lamottke, B., Tischer-Zimmermann, S., Schultze-Florey, R., Goudeva, L., Heuft, H.G., Arseniev, L., Beier, R., Beutel, G., Cario, G., Fröhlich, B., Greil, J., Hansmann, L., Hasenkamp, J., Höfs, M., Hundsdoerfer, P., Jost, E., Kafa, K., Kriege, O., Kröger, N., Mathas, S., Meisel, R., Nathrath, M., Putkonen, M., Ravens, S., Reinhardt, H.C., Sala, E., Sauer, M.G, Schmitt, C., Schroers, R., Steckel, N.K., Trappe, R.U., Verbeek, M., Wolff, D., Blasczyk, R., Eiz-Vesper, B. and Maecker-Kolhoff, B.
Journal of Clinical Investigation 133 (12): e163548. 15 June 2023

N6-methyladenine-mediated aberrant activation of the lncRNA SOX2OT-GLI1 loop promotes non-small-cell lung cancer stemness.
Dong, Hongliang, Zeng, Lili, Chen, Weiwei, Zhang, Qian, Wang, Fei, Wu, Yan, Cui, Bingjie, Qi, Jingjing, Zhang, Xin, Liu, Cuilan, Deng, Jiong, Yu, Y., Schmitt, C.A. and Du, Jing
Cell Death Discovery 9 (1): 149. 6 May 2023

COVID-19 and cellular senescence.
Schmitt, C.A., Tchkonia, T., Niedernhofer, L.J., Robbins, P.D., Kirkland, J.L. and Lee, S.
Nature Reviews Immunology 23 (4): 251-263. April 2023

Daratumumab as a novel treatment option in refractory ITP.
Vernava, I. and Schmitt, C.A.
Blood Cells Molecules and Diseases 99 : 102724. March 2023

Simultaneous imaging and flow-cytometry-based detection of multiple fluorescent senescence markers in therapy-induced senescent cancer cells.
Dovjak, E., Mairhofer, M., Wöß, C., Qi, J., Fan, D.N.Y., Schmitt, C.A. and Yu, Y.
Journal of Visualized Experiments (185): e63973. 12 July 2022

Evidence for recombinant GRP78, CALR, PDIA3 and GPI as mediators of genetic instability in human CD34+ cells.
Fabarius, A., Samra, V., Drews, O., Mörz, H., Bierbaum, M., Darwich, A., Weiss, C., Brendel, S., Kleiner, H., Seifarth, W., Greffrath, W., Hofmann, W.K., Schmitt, C.A. and Popp, H.D.
Cancers 14 (12): 2883. 11 June 2022

The genomic and transcriptional landscape of primary central nervous system lymphoma.
Radke, J., Ishaque, N., Koll, R., Gu, Z., Schumann, E., Sieverling, L., Uhrig, S., Hübschmann, D., Toprak, U.H., López, C., Hostench, X.P., Borgoni, S., Juraeva, D., Pritsch, F., Paramasivam, N., Balasubramanian, G.P., Schlesner, M., Sahay, S., Weniger, M., Pehl, D., Radbruch, H., Osterloh, A., Korfel, A., Misch, M., Onken, J., Faust, K., Vajkoczy, P., Moskopp, D., Wang, Y., Jödicke, A., Trümper, L., Anagnostopoulos, I., Lenze, D., Küppers, R., Hummel, M., Schmitt, C.A., Wiestler, O.D., Wolf, S., Unterberg, A., Eils, R., Herold-Mende, C., Brors, B., Siebert, R., Wiemann, S. and Heppner, F.L.
Nature Communications 13 (1): 2558. 10 May 2022

DLBCL 1L-what to expect beyond R-CHOP?
Stegemann, M., Denker, S. and Schmitt, C.A.
Cancers 14 (6): 1453. 11 March 2022

SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.
Wilke, A.C., Doebele, C., Zindel, A., Lee, K.S., Rieke, S.A., Ceribelli, M., Comoglio, F., Phelan, J.D., Wang, J.Q., Pikman, Y., Jahn, D., Häupl, B., Schneider, C., Scheich, S., Tosto, F.A., Bohnenberger, H., Stauder, P., Schnütgen, F., Slabicki, M., Coulibaly, Z.A., Wolf, S., Bojarczuk, K., Chapuy, B., Brandts, C.H., Stroebel, P., Lewis, C.A., Engelke, M., Xu, X., Kim, H., Dang, T.H., Schmitz, R., Hodson, D.J., Stegmaier, K., Urlaub, H., Serve, H., Schmitt, C.A., Kreuz, F., Knittel, G., Rabinowitz, J.D., Reinhardt, H.C., Vander Heiden, M.G., Thomas, C., Staudt, L.M., Zenz, T. and Oellerich, T.
Blood 139 (4): 538-553. 27 January 2022

Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.
Denker, S., Bittner, A., Frick, M., Kase, J., Hoffmann, J., Trenker, C., Keller, U., Bogner, C., Hüttmann, A., Dürig, J., Janz, M., Mathas, S., Marks, R., Krohn, U., Na, I.K., Bullinger, L. and Schmitt, C.A.
Leukemia & Lymphoma 63 (1): 84-92. January 2022

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.
Gampenrieder, S.P., Rinnerthaler, G., Tinchon, C., Petzer, A., Balic, M., Heibl, S., Schmitt, C., Zabernigg, A.F., Egle, D., Sandholzer, M., Singer, C.F., Roitner, F., Hager, C., Andel, J., Hubalek, M., Knauer, M. and Greil, R.
Breast Cancer Research 23 (1): 112. 14 December 2021

Cancer stem cells: advances in biology and clinical translation -- a Keystone Symposia report.
Cable, J., Pei, D., Reid, L.M., Wang, X.W., Bhatia, S., Karras, P., Melenhorst, J.J., Grompe, M., Lathia, J.D., Song, E., Kuo, C.J., Zhang, N., White, R.M., Ma, S.K., Ma, L., Chin, Y.R., Shen, M.M., Ng, I.O.L., Kaestner, K.H., Zhou, L., Sikandar, S., Schmitt, C.A., Guo, W., Wong, C.C.L., Ji, J., Tang, D.G., Dubrovska, A., Yang, C., Wiedemeyer, W.R. and Weissman, I.L.
Annals of the New York Academy of Sciences 1506 (1): 142–163. December 2021

Virus-induced senescence is driver and therapeutic target in COVID-19.
Lee, S., Yu, Y., Trimpert, J., Benthani, F., Mairhofer, M., Richter-Pechanska, P., Wyler, E., Belenki, D., Kaltenbrunner, S., Pammer, M., Kausche, L., Firsching, T.C., Dietert, K., Schotsaert, M., Martínez-Romero, C., Singh, G., Kunz, S., Niemeyer, D., Ghanem, R., Salzer, H.J.F., Paar, C., Mülleder, M., Uccellini, M., Michaelis, E.G., Khan, A., Lau, A., Schönlein, M., Habringer, A., Tomasits, J., Adler, J.M., Kimeswenger, S., Gruber, A.D., Hoetzenecker, W., Steinkellner, H., Purfuerst, B., Motz, R., Di Pierro, F., Lamprecht, B., Osterrieder, N., Landthaler, M., Drosten, C., García-Sastre, A., Langer, R., Ralser, M., Eils, R., Reimann, M., Fan, D.N.Y. and Schmitt, C.A.
Nature 599 : 283-289. 11 November 2021

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6).
Rinnerthaler, G., Gampenrieder, S.P., Petzer, A., Hubalek, M., Petru, E., Sandholzer, M., Andel, J., Balic, M., Melchardt, T., Hauser-Kronberger, C., Schmitt, C.A., Ulmer, H. and Greil, R.
Therapeutic Advances in Medical Oncology 13 : 17588359211042301. 19 October 2021

MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I.
Brägelmann, J., Lorenz, C., Borchmann, S., Nishii, K., Wegner, J., Meder, L., Ostendorp, J., Ast, D.F., Heimsoeth, A., Nakasuka, T., Hirabae, A., Okawa, S., Dammert, M.A., Plenker, D., Klein, S., Lohneis, P., Gu, J., Godfrey, L.K., Forster, J., Trajkovic-Arsic, M., Zillinger, T., Haarmann, M., Quaas, A., Lennartz, S., Schmiel, M., D'Rozario, J., Thomas, E.S., Li, H., Schmitt, C.A., George, J., Thomas, R.K., von Karstedt, S., Hartmann, G., Büttner, R., Ullrich, R.T., Siveke, J.T., Ohashi, K., Schlee, M. and Sos, M.L.
Nature Communications 12 (1): 5505. 17 September 2021

Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.
Reimann, M., Schrezenmeier, J.F., Richter-Pechanska, P., Dolnik, A., Hick, T.P., Schleich, K., Cai, X., Fan, D.N.Y., Lohneis, P., Masswig, S., Denker, S., Busse, A., Knittel, G., Flümann, R., Childs, D., Childs, L., Gätjens-Sanchez, A.M., Bullinger, L., Rosenwald, A., Reinhardt, H.C. and Schmitt, C.A.
Blood 137 (20): 2785-2899. 20 May 2021

Transcriptional repression of NFKBIA triggers constitutive IKK- and proteasome-independent p65/RelA activation in senescence.
Kolesnichenko, M., Mikuda, N., Höpken, U.E., Kärgel, E., Uyar, B., Tufan, A.B., Milanovic, M., Sun, W., Krahn, I., Schleich, K., von Hoff, L., Hinz, M., Willenbrock, M., Jungmann, S., Akalin, A., Lee, S., Schmidt-Ullrich, R., Schmitt, C.A. and Scheidereit, C.
EMBO Journal 40 (6): e104296. 15 March 2021

An autochthonous mouse model of Myd88- and BCL2-driven diffuse large B-cell lymphoma reveals actionable molecular vulnerabilities.
Flümann, R., Rehkämper, T., Nieper, P., Pfeiffer, P., Holzem, A., Klein, S., Bhatia, S., Kochanek, M., Kisis, I., Pelzer, B.W., Ahlert, H., Hauer, J., da Palma Guerreiro, A., Ryan, J.A., Reimann, M., Riabinska, A., Wiederstein, J., Krüger, M., Deckert, M., Altmüller, J., Klatt, A.R., Frenzel, L.P., Pasqualucci, L., Béguelin, W., Melnick, A.M., Sander, S., Montesinos-Rongen, M., Brunn, A., Lohneis, P., Büttner, R., Kashkar, H., Borkhardt, A., Letai, A., Persigehl, T., Peifer, M., Schmitt, C.A., Reinhardt, H.C. and Knittel, G.
Blood Cancer Discovery 2 (1): 70-91. January 2021

Clinical outcome in patients with carcinoma of the esophagogastric junction treated with neoadjuvant radiochemotherapy or perioperative chemotherapy: a two-enter retrospective analysis.
Wundsam, H.V., Doleschal, B., Prommer, R., Venhoda, C., Schmitt, C., Petzer, A., Metz-Gercek, S. and Rumpold, H.
Oncology 98 (10): 706-713. October 2020

ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study.
Mondello, P., Musolino, C., Dogliotti, I., Bohn, J.P., Cavallo, F., Ferrero, S., Botto, B., Cerchione, C., Nappi, D., De Lorenzo, S., Martinelli, G., Wolf, D., Schmitt, C., Loseto, G., Cuzzocrea, S., Willenbacher, W., Mian, M. and Straus, D.J.
American Journal of Hematology 95 (9): 1030-1037. September 2020

H3K9me3-mediated epigenetic regulation of senescence in mice predicts outcome of lymphoma patients.
Schleich, K., Kase, J., Dörr, J.R., Trescher, S., Bhattacharya, A., Yu, Y., Wailes, E.M., Fan, D.N.Y., Lohneis, P., Milanovic, M., Lau, A., Lenze, D., Hummel, M., Chapuy, B., Leser, U., Reimann, M., Lee, S. and Schmitt, C.A.
Nature Communications 11 (1): 3651. 20 July 2020

AP-1 imprints a reversible transcriptional programme of senescent cells.
Martínez-Zamudio, R.I., Roux, P.F., de Freitas, J.A.N.L.F., Robinson, L., Doré, G., Sun, B., Belenki, D., Milanovic, M., Herbig, U., Schmitt, C.A., Gil, J. and Bischof, O.
Nature Cell Biology 22 (7): 842-855. July 2020

Local and central evaluation of HER2 positivity and clinical outcome in advanced gastric and gastroesophageal cancer: results from the AGMT GASTRIC-5 Registry.
Huemer, F., Weiss, L., Regitnig, P., Winder, T., Hartmann, B., Thaler, J., Piringer, G., Schmitt, C.A., Eisterer, W., Gänzer, H., Wüstner, Al., Andel, J., Jagdt, B., Ulmer, H., Greil, R. and Wöll, E.
Journal of Clinical Medicine 9 (4): 935. 29 March 2020

Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network.
Greinix, H.T., Attarbaschi, A., Girschikofsky, M., Greil, R., Holter, W., Neumeister, P., Peters, C., Petzer, A., Rudzki, J., Schlenke, P., Schmitt, C.A., Schwinger, W., Wolf, D., Worel, N. and Jaeger, U.
memo: Magazine of European Medical Oncology 13 (1): 27-31. March 2020

A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response.
Denker, S., Bittner, A., Na, I.K., Kase, J., Frick, M., Anagnostopoulos, I., Hummel, M. and Schmitt, C.A.
International Journal of Hematologic Oncology 8 (4): IJH20. 19 December 2019

Non-invasive metastasis prognosis from plasma metabolites in stage II colorectal cancer patients: the DACHS study.
Zaimenko, I., Jaeger, C., Brenner, H., Chang-Claude, J., Hoffmeister, M., Grötzinger, C., Detjen, K., Burock, S., Schmitt, C.A., Stein, U. and Lisec, J.
International Journal of Cancer 145 (1): 221-231. 1 July 2019

HDAC4 mutations cause diabetes and induce β-cell FoxO1 nuclear exclusion.
Gong, M., Yu, Y., Liang, L., Vuralli, D., Froehler, S., Kuehnen, P., Du Bois, P., Zhang, J., Cao, A., Liu, Y., Hussain, K., Fielitz, J., Jia, S., Chen, W. and Raile, K.
Molecular Genetics & Genomic Medicine 7 (5): e602. May 2019

Epigenetic co-deregulation of EZH2/TET1 is a senescence-countering, actionable vulnerability in triple-negative breast cancer.
Yu, Y., Qi, J., Xiong, J., Jiang, L., Cui, D., He, J., Chen, P., Li, L., Wu, C., Ma, T., Shao, S., Wang, J., Yu, D., Zhou, B., Huang, D., Schmitt, C.A. and Tao, R.
Theranostics 9 (3): 761-777. 24 January 2019

Genotoxic stress-induced senescence.
Fan, D.N.Y. and Schmitt, C.A.
Methods in Molecular Biology 1896 : 93-105. 2019

Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis.
Arends, C.M., Galan-Sousa, J., Hoyer, K., Chan, W., Jäger, M., Yoshida, K., Seemann, R., Noerenberg, D., Waldhueter, N., Fleischer-Notter, H., Christen, F., Schmitt, C.A., Dörken, B., Pelzer, U., Sinn, M., Zemojtel, T., Ogawa, S., Märdian, S., Schreiber, A., Kunitz, A., Krüger, U., Bullinger, L., Mylonas, E., Frick, M. and Damm, F.
Leukemia 32 (9): 1908-1919. September 2018

Nontargeted identification of tracer incorporation in high-resolution mass spectrometry.
Hoffmann, F., Jaeger, C., Bhattacharya, A., Schmitt, C.A. and Lisec, J.
Analytical Chemistry 90 (12): 7253-7260. 19 June 2018

Targeting the senescence-overriding cooperative activity of structurally unrelated H3K9 demethylases in melanoma.
Yu, Y., Schleich, K., Yue, B., Ji, S., Lohneis, P., Kemper, K., Silvis, M.S., Qutob, N., van Rooijen, E., Werner-Klein, M., Li, L., Dhawan, D., Meierjohann, S., Reimann, M., Elkahloun, A., Treitschke, S., Dörken, B., Speck, C., Mallette, F.A., Zon, L.I., Holmen, S.L., Peeper, D.S., Samuels, Y., Schmitt, C.A. and Lee, S.
Cancer Cell 33 (2): 322-336. 12 February 2018

Senescence-associated reprogramming promotes cancer stemness.
Milanovic, M., Fan, D.N.Y., Belenki, D., Däbritz, J.H.M., Zhao, Z., Yu, Y., Dörr, J.R., Dimitrova, L., Lenze, D., Monteiro Barbosa, I.A., Mendoza-Parra, M.A., Kanashova, T., Metzner, M., Pardon, K., Reimann, M., Trumpp, A., Dörken, B., Zuber, J., Gronemeyer, H., Hummel, M., Dittmar, G., Lee, S. and Schmitt, C.A.
Nature 553 (7686): 96-100. 4 January 2018

The Ink4a/Arf locus operates as a regulator of the circadian clock modulating RAS activity.
El-Athman, R., Genov, N.N., Mazuch, J., Zhang, K., Yu, Y., Fuhr, L., Abreu, M., Li, Y., Wallach, T., Kramer, A., Schmitt, C.A. and Relógio, A.
PLoS Biology 15 (12): e2002940. 7 December 2017

Decitabine inhibits T cell proliferation via a novel TET2-dependent mechanism and exerts potent protective effect in mouse auto- and allo-immunity models.
Wang, X., Wang, J., Yu, Y., Ma, T., Chen, P., Zhou, B. and Tao, R.
Oncotarget 8 (34): 56802-56815. 22 August 2017

Compound annotation in liquid chromatography/high-resolution mass spectrometry based metabolomics: robust adduct ion determination as a prerequisite to structure prediction in electrospray ionization mass spectra.
Jaeger, C., Méret, M., Schmitt, C.A. and Lisec, J.
Rapid Communications in Mass Spectrometry 31 (15): 1261-1266. 15 August 2017

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.
Young, E., Noerenberg, D., Mansouri, L., Ljungström, V., Frick, M., Sutton, L.A., Blakemore, S.J., Galan-Sousa, J., Plevova, K., Baliakas, P., Rossi, D., Clifford, R., Roos-Weil, D., Navrkalova, V., Dörken, B., Schmitt, C.A., Smedby, K.E., Juliusson, G., Giacopelli, B., Blachly, J.S., Belessi, C., Panagiotidis, P., Chiorazzi, N., Davi, F., Langerak, A.W., Oscier, D., Schuh, A., Gaidano, G., Ghia, P., Xu, W., Fan, L., Bernard, O.A., Nguyen-Khac, F., Rassenti, L., Li, J., Kipps, T.J., Stamatopoulos, K., Pospisilova, S., Zenz, T., Oakes, C.C., Strefford, J.C., Rosenquist, R. and Damm, F.
Leukemia 31 (7): 1547-1554. July 2017

Initiation of acute graft-versus-host disease by angiogenesis.
Riesner, K., Shi, Y., Jacobi, A., Kräter, M., Kalupa, M., McGearey, A., Mertlitz, S., Cordes, S., Schrezenmeier, J.F., Mengwasser, J., Westphal, S., Perez-Hernandez, D., Schmitt, C., Dittmar, G., Guck, J. and Penack, O.
Blood 129 (14): 2021-2032. 6 April 2017

Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin's lymphoma.
Du, J., Neuenschwander, M., Yu, Y., Däbritz, J.H.M., Neuendorff, N.R., Schleich, K., Bittner, A., Milanovic, M., Beuster, G., Radetzki, S., Specker, E., Reimann, M., Rosenbauer, F., Mathas, S., Lohneis, P., Hummel, M., Dörken, B., von Kries, J.P., Lee, S. and Schmitt, C.A.
Blood 129 (1): 71-81. 5 January 2017

Detecting markers of therapy-induced senescence in cancer cells.
Fan, D.N.Y. and Schmitt, C.A.
Methods in Molecular Biology 1534 : 41-52. 2017

Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma.
Mansouri, L., Noerenberg, D., Young, E., Mylonas, E., Abdulla, M., Frick, M., Asmar, F., Ljungstroem, V., Schneider, M., Yoshida, K., Skaftason, A., Pandzic, T., Gonzalez, B., Tasidou, A., Waldhueter, N., Rivas-Delgado, A., Angelopoulou, M., Ziepert, M., Arends, C.M., Couronne, L., Lenze, D., Baldus, C.D., Bastard, C., Okosun, J., Fitzgibbon, J., Doerken, B., Drexler, H.G., Roos-Weil, D., Schmitt, C.A., Munch-Petersen, H.D., Zenz, T., Hansmann, M.L., Strefford, J.C., Enblad, G., Bernard, O.A., Ralfkiaer, E., Erlanson, M., Korkolopoulou, P., Hultdin, M., Papadaki, T., Gronbaek, K., Lopez-Guillermo, A., Ogawa, S., Kueppers, R., Stamatopoulos, K., Stavroyianni, N., Kanellis, G., Rosenwald, A., Campo, E., Amini, R.M., Ott, G., Vassilakopoulos, T.P., Hummel, M., Rosenquist, R. and Damm, F.
Blood 128 (23): 2666-2670. 15 December 2016

Automated annotation and evaluation of in-source mass spectra in GC/atmospheric pressure chemical ionization-MS-based metabolomics.
Jaeger, C., Hoffmann, F., Schmitt, C.A. and Lisec, J.
Analytical Chemistry 88 (19): 9386-9390. 4 October 2016

New Wnt/β-catenin target genes promote experimental metastasis and migration of colorectal cancer cells through different signals.
Qi, J., Yu, Y., Akilli Öztürk, Ö., Holland, J.D., Besser, D., Fritzmann, J., Wulf-Goldenberg, A., Eckert, K., Fichtner, I. and Birchmeier, W.
Gut 65 (10): 1690-1701. October 2016

Extending the dynamic range in metabolomics experiments by automatic correction of peaks exceeding the detection limit.
Lisec, J., Hoffmann, F., Schmitt, C. and Jaeger, C.
Analytical Chemistry 88 (15): 7487-7492. 2 August 2016

B cell-specific conditional expression of Myd88(p.L252P) leads to the development of diffuse large B cell lymphoma in mice.
Knittel, G., Liedgens, P., Korovkina, D., Seeger, J.M., Al-Baldawi, Y., Al-Maarri, M., Fritz, C., Vlantis, K., Bezhanova, S., Scheel, A.H., Wolz, O.O., Reimann, M., Möller, P., López, C., Schlesner, M., Lohneis, P., Weber, A.N.R., Trümper, L., Staudt, L.M., Ortmann, M., Pasparakis, M., Siebert, R., Schmitt, C.A., Klatt, A.R., Wunderlich, F.T., Schäfer, S.C., Persigehl, T., Montesinos-Rongen, M., Odenthal, M., Büttner, R., Frenzel, L.P., Kashkar, H. and Reinhardt, H.C.
Blood 127 (22): 2732-2741. 2 June 2016

CD20-targeting immunotherapy promotes cellular senescence in B-cell lymphoma.
Däbritz, J.H.M., Yu, Y., Milanovic, M., Schönlein, M., Rosenfeldt, M.T., Dörr, J.R., Kaufmann, A.M., Dörken, B. and Schmitt, C.A.
Molecular Cancer Therapeutics 15 (5): 1074-1081. May 2016

Neutropenic sepsis in the ICU: Outcome predictors in a two-phase model and microbiology findings.
Kruse, J.M., Jenning, T., Rademacher, S., Arnold, R., Schmitt, C.A., Jörres, A., Enghard, P. and Oppert, M.
Critical Care Research and Practice 2016 : 8137850. 2016

Glioma-derived versican promotes tumor expansion via glioma-associated microglial/macrophages Toll-like receptor 2 signaling.
Hu, F., a Dzaye, O.D., Hahn, A., Yu, Y., Scavetta, R.J., Dittmar, G., Kaczmarek, A.K., Dunning, K.R., Ricciardelli, C., Rinnenthal, J.L., Heppner, F.L., Lehnardt, S., Synowitz, M., Wolf, S.A. and Kettenmann, H.
Neuro-Oncology 17 (2): 200-210. February 2015

Synthetic lethal metabolic targeting of cellular senescence in cancer therapy.
Dörr, J.R., Yu, Y., Milanovic, M., Beuster, G., Zasada, C., Däbritz, J.H.M., Lisec, J., Lenze, D., Gerhardt, A., Schleicher, K., Kratzat, S., Purfürst, B., Walenta, S., Mueller-Klieser, W., Gräler, M., Hummel, M., Keller, U., Buck, A.K., Dörken, B., Willmitzer, L., Reimann, M., Kempa, S., Lee, S. and Schmitt, C.A.
Nature 501 (7467): 421-425. 19 September 2013

Combined inhibition of PI3K-related DNA-damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas.
Shortt, J., Martin, B.P., Newbold, A., Hannan, K.M., Devlin, J.R., Baker, A.J., Ralli, R., Cullinane, C., Schmitt, C.A., Reimann, M., Hall, M.N., Wall, M., Hannan, R.D., Pearson, R.B., McArthur, G.A. and Johnstone, R.W.
Blood 121 (15): 2964-2974. 11 April 2013

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Bywater, M.J., Poortinga, G., Sanij, E., Hein, N., Peck, A., Cullinane, C., Wall, M., Cluse, L., Drygin, D., Anderes, K., Huser, N., Proffitt, C., Bliesath, J., Haddach, M., Schwaebe, M.K., Ryckman, D.M., Rice, W.G., Schmitt, C., Lowe, S.W., Johnstone, R.W., Pearson, R.B., McArthur, G.A. and Hannan, R.D.
Cancer Cell 22 (1): 51-65. 10 July 2012

Stromal interferon-γ signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in mice.
Gerbitz, A., Sukumar, M., Helm, F., Wilke, A., Friese, C., Fahrenwaldt, C., Lehmann, F.M., Loddenkemper, C., Kammertoens, T., Mautner, J., Schmitt, C.A., Blankenstein, T. and Bornkamm, G.W.
PLoS ONE 7 (3): e34552. 30 March 2012

Reduced tumor-antigen density leads to PD-1/PD-L1 mediated impairment of partially exhausted CD8(+) T cells.
Kaiser, A.D., Schuster, K., Gadiot, J., Borkner, L., Daebritz, H., Schmitt, C., Andreesen, R. and Blank, C.
European Journal of Immunology 42 (3): 662-671. March 2012

Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations.
Jing, H., Kase, J., Dörr, J.R., Milanovic, M., Lenze, D., Grau, M., Beuster, G., Ji, S., Reimann, M., Lenz, P., Hummel, M., Doerken, B., Lenz, G., Scheidereit, C., Schmitt, C.A. and Lee, S.
Genes & Development 25 (20): 2137-2146. 15 October 2011

Cellular senescence predicts treatment outcome in metastasised colorectal cancer.
Haugstetter, A.M., Loddenkemper, C., Lenze, D., Groene, J., Standfuss, C., Petersen, I., Doerken, B. and Schmitt, C.A.
British Journal of Cancer 103 (4): 505-509. 10 August 2010

Hypoxia-inducible factor 1α determines gastric cancer chemosensitivity via modulation of p53 and NF-κB.
Rohwer, N., Dame, C., Haugstetter, A.M., Wiedenmann, B., Detjen, K., Schmitt, C.A. and Cramer, T.
PLoS ONE 5 (8): e12038. 10 August 2010

Tumor stroma-derived TGF-beta limits Myc-driven lymphomagenesis via Suv39h1-dependent senescence.
Reimann, M., Lee, S., Loddenkemper, C., Dörr, J.R., Tabor, V., Aichele, P., Stein, H., Doerken, B., Jenuwein, T. and Schmitt, C.A.
Cancer Cell 17 (3): 262-272. 16 March 2010

FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf.
Bouchard, C., Lee, S., Paulus-Hock, V., Loddenkemper, C., Eilers, M. and Schmitt, C.A.
Genes & Development 21 (21): 2775-2787. 1 November 2007

The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo.
Reimann, M., Loddenkemper, C., Rudolph, C., Schildhauer, I., Teichmann, B., Stein, H., Schlegelberger, B., Doerken, B. and Schmitt, C.A.
Blood 110 (8): 2996-3004. 15 October 2007

Oncogene-induced senescence as an initial barrier in lymphoma development.
Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A.H., Schlegelberger, B., Stein, H., Doerken, B., Jenuwein, T. and Schmitt, C.A.
Nature 436 (7051): 660-665. 4 August 2005

Recurrent chromosomal aberrations in INK4a/ARF defective primary lymphomas predict drug responses in vivo.
Helmrich, A., Lee, S., O'Brien, P., Doerken, B., Lowe, S.W., Schroeck, E. and Schmitt, C.A.
Oncogene 24 : 4174-4182. 1 January 2005

Cellular senescence in cancer treatment: friend or foe?
Kahlem, P., Doerken, B. and Schmitt, C.A.
Journal of Clinical Investigation 113 (2): 169-174. January 2004

Inter and intraobserver variability in DePalma's classification of shoulder calcific tendinitis.
Maier, M., Maier-Bosse, T., Schulz, C.U., Steinborn, M., Schmitt, C.A., Kleen, M. and Staebler, A.
Journal of Rheumatology 30 (5): 1029-1031. May 2003

Book Section

Apoptosis and cancer therapy.
Reimann, M. and Schmitt, C.A.
In: Apoptosis, Cell Signaling, and Human Diseases. Humana Press, 303-320. ISBN 978-1-58829-677-1 2007

Mouse models in cancer research.
Lee, S. and Schmitt, C.A.
In: Apoptosis and Cancer Therapy: From Cutting-edge Science to Novel Therapeutic Concepts. UNSPECIFIED, 671-701. ISBN 9783527312375 6 February 2006

Book

Metabolism in cancer.
Cramer, T. and Schmitt, C., eds.
Recent Results in Cancer Research, 207 . Springer. ISBN 978-3-319-42118-6 2016

Review

Cellular senescence: Neither irreversible nor reversible.
Reimann, M., Lee, S. and Schmitt, C.A.
Journal of Experimental Medicine 221 (4): e20232136. 1 April 2024

Protein biomarkers in blood reflect the interrelationships between stroke outcome, inflammation, coagulation, adhesion, senescence and cancer.
Fuellen, G., Walter, U., Henze, L., Böhmert, J., Palmer, D., Lee, S., Schmitt, C.A., Rudolf, H. and Kowald, A.
Cellular and Molecular Neurobiology 43 (4): 1413-1424. May 2023

Senescence and cancer - role and therapeutic opportunities.
Schmitt, C.A., Wang, B. and Demaria, M.
Nature Reviews Clinical oncology 19 (10): 619–636. October 2022

ASH highlights 2019: "aggressive B-cell lymphoma".
Schmitt, C.A.
memo: Magazine of European Medical Oncology 13 (3): 266-269. 20 May 2020

Cellular senescence: defining a path forward.
Gorgoulis, V., Adams, P.D., Alimonti, A., Bennett, D.C., Bischof, O., Bishop, C., Campisi, J., Collado, M., Evangelou, K., Ferbeyre, G., Gil, J., Hara, E., Krizhanovsky, V., Jurk, D., Maier, A.B., Narita, M., Niedernhofer, L., Passos, J.F., Robbins, P.D., Schmitt, C.A., Sedivy, J., Vougas, K., von Zglinicki, T., Zhou, D., Serrano, M. and Demaria, M.
Cell 179 (4): 813-827. 31 October 2019

The dynamic nature of senescence in cancer.
Lee, S. and Schmitt, C.A.
Nature Cell Biology 21 (1): 94-101. January 2019

The Senescence-Stemness Alliance - a cancer-hijacked regeneration principle.
Milanovic, M., Yu, Y. and Schmitt, C.A.
Trends in Cell Biology 28 (12): 1049-1061. December 2018

NF-κB in cellular senescence and cancer treatment.
Jing, H. and Lee, S.
Molecules and Cells 37 (3): 189-195. 31 March 2014

The Myc/macrophage tango: Oncogene-induced senescence, Myc style.
Lee, S., Schmitt, C.A. and Reimann, M.
Seminars in Cancer Biology 21 (6): 377-384. December 2011

Non-cell-autonomous tumor suppression: oncogene-provoked apoptosis promotes tumor cell senescence via stromal crosstalk.
Reimann, M., Schmitt, C.A. and Lee, S.
Journal of Molecular Medicine 89 (9): 869-875. September 2011

Cellular senescence and cancer treatment.
Schmitt, C.A.
Biochimica et Biophysica Acta - Reviews on Cancer 1775 (1): 5-20. January 2007

Oncogene-induced senescence: putting the brakes on tumor development.
Braig, M. and Schmitt, C.A.
Cancer Research 66 (6): 2881-2884. 15 March 2006

Senescence apoptosis and therapy - cutting the lifelines of cancer.
Schmitt, C.A.
Nature Reviews Cancer 3 (4): 286-295. April 2003

Chemotherapy response and resistance.
Lee, S. and Schmitt, C.A.
Current Opinion in Genetics & Development 13 (1): 90-96. February 2003

Apoptosis and chemoresistance in transgenic cancer models.
Schmitt, C.A. and Lowe, S.W.
Journal of Molecular Medicine 80 (3): 137-146. March 2002

Letter

Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer.
Mairhofer, M., Kausche, L., Kaltenbrunner, S., Ghanem, R., Stegemann, M., Klein, K., Pammer, M., Rauscher, I., Salzer, H.J.F., Doppler, S., Habringer, A., Paar, C., Kimeswenger, S., Hoetzenecker, W., Lamprecht, B., Lee, S. and Schmitt, C.A.
Cancer Cell 39 (9): 1171-1172. 13 September 2021

Cerebral EBV-positive PTLD controlled by PD-1 checkpoint blockade in a liver transplant patient.
Bittner, A., Radke, J., Eurich, D., Wiener, E., Denker, S., Anagnostopoulos, I., Na, I.K., Heppner, F.L., Bullinger, L. and Schmitt, C.A.
Leukemia & Lymphoma 62 (8): 2026-2029. August 2021

T cell PTLD successfully treated with single-agent brentuximab vedotin first-line therapy.
Choi, M., Fink, S., Prasad, V., Anagnostopoulos, I., Reinke, P. and Schmitt, C.A.
Transplantation 100 (3): e8-e10. March 2016

Extramedullary manifestation of a donor-derived acute myeloid leukemia in a liver transplant patient.
Subklewe, M., Nagy, M., Schoch, C., Jenisch, S., Siebert, R., Gesk, S., Neuhaus, P., Doerken, B. and Schmidt, C.A.
Leukemia 18 (12): 2050-2053. 7 October 2004

Extracorporeal photopheresis in graft-versus-host disease: ultraviolet radiation mediates T cell senescence in vivo.
Lee, S., Doerken, B. and Schmitt, C.A.
Transplantation 78 (3): 484-485. 15 August 2004

Editorial

A cFLIP-flop switch for senolysis.
Fan, D.N.Y. and Schmitt, C.A.
Nature Cancer 3 (11): 1279-1281. November 2022

COVID-19: new disease mechanism is simultaneously a therapeutic target.
Schmitt, C.A.
memo: Magazine of European Medical Oncology 15 (2): 100-101. June 2022

Therapy-induced senescence: opportunities to improve anticancer therapy.
Prasanna, P.G., Citrin, D.E., Hildesheim, J., Ahmed, M.M., Venkatachalam, S., Riscuta, G., Xi, D., Zheng, G., van Deursen, J., Goronzy, J., Kron, S.J., Anscher, M.S., Sharpless, N.E., Campisi, J., Brown, S.L., Niedernhofer, L.J., O'Loghlen, A., Georgakilas, A.G., Paris, F., Gius, D., Gewirtz, D.A., Schmitt, C.A., Abazeed, M.E., Kirkland, J.L., Richmond, A., Romesser, P.B., Lowe, S.W., Gil, J., Mendonca, M.S., Burma, S., Zhou, D. and Coleman, C.N.
Journal of the National Cancer Institute 113 (10): 1285-1298. October 2021

Editorial: critical issues in lymphoma management.
Fuchs, D. and Schmitt, C.A.
memo: Magazine of European Medical Oncology 12 (1): 1. March 2019

UnSASPing senescence: unmasking tumor suppression?
Schmitt, C.A.
Cancer Cell 34 (1): 6-8. 9 July 2018

The persistent dynamic secrets of senescence.
Schmitt, C.A.
Nature Cell Biology 18 (9): 913-915. September 2016

Mouse models of human cancer.
Böck, B.C., Stein, U., Schmitt, C.A. and Augustin, H.G.
Cancer Research 74 (17): 4671-4675. 1 September 2014

Preprint

Therapy-induced senescence upregulates antigen presentation machinery and triggers anti-tumor immunity in Acute Myeloid Leukemia.
Gilioli, D., Fusco, S., Tavella, T., Giannetti, K., Conti, A., Santoro, A., Carsana, E., Beretta, S., Schönlein, M., Gambacorta, V., Aletti, F.M., Carraba, M.G., Bonini, C., Ciceri, F., Merelli, I., Vago, L., Schmitt, C.A. and Di Micco, R.
bioRxiv : 2022.11.17.515658. 17 November 2022

This list was generated on Sun Dec 22 01:13:11 2024 UTC.
Open Access
MDC Library